Shimizu Akira, Kaira Kyoichi, Okubo Yuko, Utsumi Daisuke, Yasuda Masahito, Asao Takayuki, Nishiyama Masahiko, Takahashi Kenzo, Ishikawa Osamu
and Gunma University Graduate School of Medicine, Maebashi, Gunma; and and Graduate School of Medicine, University of the Ryukyus, Nishihara, Okinawa, Japan.
J Glob Oncol. 2016 Oct 5;3(4):360-369. doi: 10.1200/JGO.2016.005843. eCollection 2017 Aug.
Programmed death-1 (PD-1) or programmed death ligand-1 (PD-L1) targeted therapies have shown promising survival outcomes in several human neoplasms. However, it is unclear whether the expression of PD-L1 can be correlated to any clinical and pathologic variables in patients with cutaneous angiosarcoma (CA). The aim of this study was to evaluate the clinicopathological significance of PD-L1 expression in CA patients.
Data from 52 patients with CA were retrospectively reviewed. PD-L1 expression, tumor proliferation determined by Ki-67 index, and immunohistochemical evaluation of tumor-infiltrating lymphocytes, CD4+ and CD8+, were used to determine correlation with clinicopathological variables.
PD-L1 was positively expressed in 40% of all patients. PD-L1 expression was significantly associated with tumor cell proliferation. Multivariate analysis confirmed that high levels of CD8+ tumor-infiltrating lymphocytes were a significant predictor in patients with clinical stage I CA and the positive expression of PD-L1 was an independent prognostic factor in predicting worse outcome.
PD-L1 expression is a novel pathologic marker for predicting worse outcome in patients with CA.
程序性死亡受体1（PD-1）或程序性死亡配体1（PD-L1）靶向治疗在多种人类肿瘤中已显示出有前景的生存结果。然而，尚不清楚PD-L1的表达是否与皮肤血管肉瘤（CA）患者的任何临床和病理变量相关。本研究的目的是评估PD-L1表达在CA患者中的临床病理意义。
回顾性分析52例CA患者的数据。采用PD-L1表达、通过Ki-67指数确定的肿瘤增殖以及对肿瘤浸润淋巴细胞CD4+和CD8+的免疫组化评估来确定与临床病理变量的相关性。
所有患者中40%的PD-L1呈阳性表达。PD-L1表达与肿瘤细胞增殖显著相关。多因素分析证实，高水平的CD8+肿瘤浸润淋巴细胞是临床I期CA患者的显著预测指标，而PD-L1的阳性表达是预测预后较差的独立预后因素。
PD-L1表达是预测CA患者预后较差的一种新的病理标志物。
